Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031070 · ClinicalTrials.gov registry record · Phase 2
Increasing HAART-Induced Immune Restoration With Cyclosporine
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00031070 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 40 participants.
The verdict
NCT00031070, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to see if cyclosporine, taken when a patient begins highly active antiretroviral therapy (HAART), increases the number of CD4 T-cells (blood cells that fight infection) in a patient's blood. This study also will explore the safety of briefly giving cyclosporine to patients starting HAART.
Interventions
- DRUG Cyclosporine
- DRUG Efavirenz
- DRUG Abacavir sulfate, Lamivudine and Zidovudine
- BIOLOGICAL Pneumococcal Conjugate Vaccine, Heptavalent
- BIOLOGICAL Hepatitis A Vaccine (Inactivated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031070
The ClinicalTrials.gov registry entry for NCT00031070 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclosporine is the first listed.
NCT00031070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031070 about?
NCT00031070 is a clinical study titled "Increasing HAART-Induced Immune Restoration With Cyclosporine". The purpose of this study is to see if cyclosporine, taken when a patient begins highly active antiretroviral therapy (HAART), increases the number of CD4 T-cells (blood cells that fight infection) in a patient's blood. This study also will explore the safety of briefly giving cyclosporine to patien...
What is the current status of trial NCT00031070?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00031070?
The interventions under investigation include: Cyclosporine (DRUG), Efavirenz (DRUG), Abacavir sulfate, Lamivudine and Zidovudine (DRUG), Pneumococcal Conjugate Vaccine, Heptavalent (BIOLOGICAL), Hepatitis A Vaccine (Inactivated) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00031070?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.